Wet AMD Prior Authorization on Medicare Advantage: Track Requests and Protect Ongoing Care

If an authorization problem threatens your next wet AMD injection, tell the retina clinic promptly and ask the plan for the request’s received date, status and decision deadline. Keep the prescribed appointment date visible. A concise record can help coordination, but no cover sheet or phone script guarantees approval or prevents every delay.

U.S. Medicare Advantage information checked October 15, 2026. This guide concerns the authorization workflow for clinic-administered treatment. Your clinical team decides treatment and urgency.

Find the actual problem before repeating a submission

A delay may involve missing information, a coverage criterion, a network issue, a drug preference or a scheduling problem after approval. Different causes require different actions. Ask the clinic and plan about your actual request, rather than assuming a general benefits answer applies.

• Not received: have the clinic confirm the submission destination and proof of delivery. Ask the plan how to locate it.
• Information requested: obtain an exact list and ask the clinic who will respond. Keep the original received date as well as later submission dates.
• Approved: have the clinic check the drug, provider, location, dates and scope of the approval against the prescribed service.
• Denied or limited: obtain the written reason and appeal instructions. Repeatedly resending records should not cause you to miss an appeal deadline.

If you do not understand a status, ask for an explanation in writing. Do not assume a phone representative’s word “pending” tells you whether a formal decision has been made.

Use a shared record, rather than a promised “proof pack”

The clinic should prepare clinical documentation and billing details. You can help by keeping your plan information and treatment history available and asking who is responsible for the next action. A one-page summary is optional; it does not replace the plan’s required forms or the full medical record.

Ask the authorization team to verify:

• The exact plan and member information, using the plan’s secure channel.
• The prescribed drug, dose, frequency, diagnosis and treatment history.
• The treating provider, billing entity and actual service location.
• The correct submission route and any required clinical records.
• The requested dates, current appointment and any clinical urgency.

You do not need to choose a billing code, interpret an OCT scan or write medical-necessity claims yourself. Ask staff to correct errors. Do not alter treatment history to fit a coverage rule. Keep copies of notices and reference numbers in a place you can retrieve, and share them only with the people helping with your care.

Part B drug decision clocks are specific

For an initial Medicare Advantage Part B drug request, 42 CFR 422.568(b)(3) requires notification as quickly as health requires, no later than 72 hours after receipt. An approved expedited Part B drug determination has a maximum of 24 hours after receipt under 42 CFR 422.572(a)(2). The specified Part B drug periods cannot be extended under the extension provisions identified there.

Do not assume that an information request automatically restarts those clocks. Ask the plan to identify the applicable deadline and legal basis for any different date it gives you. Preserve both the first receipt confirmation and subsequent correspondence. Administrative follow-up and clinical advice should proceed together when the appointment is at risk.

These limits concern the specified drug decision. They are not an approval guarantee or a safe waiting period, and they are different from appeal deadlines and rules for other services. Ask the prescriber to support expedited handling when waiting for the standard process could seriously jeopardize health or function. Explain the actual clinical concern; special wording is not a substitute for it.

If you join a new plan during ongoing treatment

42 CFR 422.112(b)(8) requires Medicare Advantage coordinated care plans to provide at least a 90-day transition for an active course of treatment begun before enrollment, including treatment furnished by an out-of-network provider. The plan must not disrupt or require reauthorization of that active course during the protected period. The rule also addresses authorization validity for as long as medically necessary, consistent with coverage criteria, history and the treating provider’s recommendation.

Ask the new plan how it will honor the applicable protection. Have the clinic document the ongoing prescribed course and previous treatment dates. Confirm the plan’s effective date, appointment and billing arrangements. This is not a blanket promise that every new treatment or out-of-network visit is covered indefinitely.

A prior authorization and a drug step-therapy requirement are different issues. If the dispute is about trying another drug first, see the Part B step-therapy protection and appeal guide. Do not change plans or stop coverage as a shortcut to an immediate injection; confirm individual enrollment rights and effective dates before any change.

When a decision is unfavorable or overdue

For a denial, work from the written notice and address its stated reason with the clinic. Ask about a standard or expedited appeal, who will file it, and how you will confirm receipt. CMS explains Medicare Advantage reconsideration, including the filing deadline and separate Part B drug appeal timelines. Do not substitute a general customer-service complaint for a coverage appeal.

If the plan has not issued a timely decision, ask its appeals or member-services team how to pursue the missed deadline, retain your evidence and seek Medicare counseling if needed. Your local SHIP program can help explain Medicare processes. Meanwhile, tell the retina team that the administrative issue remains unresolved; do not decide on your own that the treatment can wait.

A call note you can copy

This is a suggested record, not an official form:

• Prescribed appointment and drug:
• Plan received date and case number:
• Current status and written reason, if any:
• Applicable decision deadline:
• Information or action still needed:
• Responsible clinic or plan contact:
• Next follow-up agreed:
• Urgent clinical contact, if timing or symptoms change:

A useful opening is: “My prescribed injection is on [date]. Please confirm when this request was received, what decision is due, and what action remains.” After the call, ask for written confirmation of an important decision. Avoid creating a new duplicate request unless the clinic and plan explain why it is necessary.

Keep authorization data separate from promises about care

Public plan metrics may provide context but cannot predict your case. The 2026 public-reporting provision in 42 CFR 422.122(c) excludes drug data. Do not interpret those reported rates as a measurement of your anti-VEGF drug’s approval likelihood.

There is no universal ten-day “safe buffer.” Follow up according to the actual appointment, decision deadline and clinical advice. New vision symptoms require medical advice separately from paperwork. Sudden inability to see or sudden severe eye pain requires emergency assessment; do not wait for an insurer to respond.

For the next visit, your practical goal is a confirmed clinical plan, a traceable coverage request and a named person responsible for the next action. That makes uncertainty visible without promising that every administrative problem has a quick fix.